What is Cytax (Paclitaxel)?
Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi’s sarcoma. Paclitaxel is also used for the prevention of restenosis.
Paclitaxel is indicated as first-line and subsequent therapy for :
- the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel is indicated in combination with cisplatin.
- the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors.
- the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
30mg (1 vial.)
100mg (1 vial.)
260mg (1 vial.)
Storage and handling:
Store at 20° to 25° C, excursions permitted to 15° to 30° C
How do we source the Drug?
SSPWL will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.
Company that Manufactures/ Markets:
M/s Intas Pharma
Assistance Cell in India:
For ONCOLOGY DRUG: price Cytax(Paclitaxel) Contact Us, by call +91 07738100125 / +91 07738151650 or by email : email@example.com